Abstract
About 21% of Taiwanese patients with major depression developed treatment-resistant depression (TRD) during 1-year follow-up in Taiwan. TRD was commonly coupled with functional impairment, poor quality of life, suicide ideation and attempts, self-injurious behaviors, and a high relapse rate. From 2012 and 2015, we had conducted the first randomized, double-blind, placebo control trial in Asian countries to examine the therapeutic efficacy of a single low-dose ketamine infusion in Taiwanese patients with TRD. Seventy one subjects were evenly distributed in three dose groups with 0.5 mg/kg, 0.2 mg/kg, and placebo, respectively. Responder was identified by response (≥50% reduction of mood ratings) at any two daily HAMD measures during the period of 24–96 h (day 2–5) post-ketamine infusion. There was a significant difference in the response rate across the three groups (0.5 mg/kg: 45.8%; 0.2 mg/kg: 39.1%; placebo: 12.5%; p = 0.03), which is much lower than that in the Caucasians (70%). Two factors might be related: lower serum ketamine levels and lower Val/Val allele percentage in BDNF Val66Met genotyping found in the Taiwanese patients. In addition to the rapid antidepressant effect of ketamine, a greater antisuicidal effect (59%) was also identified. The former may only account for 52.7% of the latter, indicating that the antisuicidality may be independent from antidepressiveness. Single dose of ketamine only resulted in short-lived psychedelic/dissociation adverse effect, which was resolved within 2 h post-infusion. Up to present, no long-term side effects were identified, given a single-dose administration. Using 18F-FDG-PET scanning and 24 h post-ketamine infusion, glucose metabolism of the prefrontal cortex (PFC), supplementary motor area (SMA), and dorsal anterior cingulate cortex (dACC) were activated immediately (40 min post-infusion), and activation of SMA and dACC could sustain for 1 day, which may contribute to the persistent antidepressant effect of ketamine beyond its half-life, suggesting that a short activation in the PFC engendered by ketamine infusion may be a kindler, facilitating the persistent increase in glucose metabolism in the SMA and dACC; therefore, the PFC may be still considered to play a key role in improving TRD. These findings were also supported by a simple wearable forehead EEG monitoring from baseline to 40 min post-infusion, revealing that ketamine may increase the theta and low alpha power and decrease asymmetry in the PFC. Finally, a maintenance trial in a double-blind, randomized fashion using a partial NMDA agonist, d-cycloserine (DCS) vs. placebo, was conducted in the ketamine responders. This DCS augmentation treatment was not superior to placebo in maintaining the initial antidepressant response to ketamine infusion, but DCS did appear to maintain the antisuicidal effect during the 6-week follow-up study.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al-Harbi KS (2012) Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 6:369–388
Bush G, Luu P, Posner MI (2000) Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci 4:215–222
Cao Z, Lin CT, Ding W, Chen MH, Li CT, Su TP (2018) Identifying ketamine responses in treatment-resistant depression using a wearable forehead EEG. IEEE Trans Biomed Eng. https://doi.org/10.1109/TBME.2018.2877651
Carlson PJ, Diazgranados N, Nugent AC, Ibrahim L, Luckenbaugh DA, Brutsche N, Herscovitch P, Manji HK, Zarate CA Jr, Drevets WC (2013) Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol Psychiatry 73:1213–1221
Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, Cheng CM, Su TP (2018a) Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion. J Affect Disord 241:1–7
Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, Cheng CM, Su TP (2018b) Persistent antidepressant effect of low-dose ketamine and activation in the supplementary motor area and anterior cingulate cortex in treatment-resistant depression: a randomized control study. J Affect Disord 225:709–714
Chen MH, Lin WC, Wu HJ, Cheng CM, Li CT, Hong CJ, Tu PC, Bai YM, Tsai SJ, Su TP (2019) Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD). J Affect Disord 251:162–169
Cheng WJ, Chen CH, Chen CK, Huang MC, Pietrzak RH, Krystal JH, Xu K (2018) Similar psychotic and cognitive profile between ketamine dependence with persistent psychosis and schizophrenia. Schizophr Res 199:313–318
Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, Tse JM, Lau FL, Yiu MK, Man CW (2008) The destruction of the lower urinary tract by ketamine abuse: a new syndrome? BJU Int 102:1616–1622
De Raedt R, Vanderhasselt MA, Baeken C (2015) Neurostimulation as an intervention for treatment resistant depression: from research on mechanisms towards targeted neurocognitive strategies. Clin Psychol Rev 41:61–69
Ding R, Li Y, Du A, Yu H, He B, Shen R, Zhou J, Li L, Cui W, Zhang G, Lu Y, Wu X (2016) Changes in hippocampal AMPA receptors and cognitive impairments in chronic ketamine addiction models: another understanding of ketamine CNS toxicity. Sci Rep 6:38771
Drevets WC, Price JL, Furey ML (2008) Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213:93–118
Fife D, Feng Y, Wang MY, Chang CJ, Liu CY, Juang HT, Furnback W, Singh J, Wang B (2017) Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res 252:277–283
Fu TS, Lee CS, Gunnell D, Lee WC, Cheng AT (2013) Changing trends in the prevalence of common mental disorders in Taiwan: a 20-year repeated cross-sectional survey. Lancet 381:235–241
Gollan JK, Hoxha D, Chihade D, Pflieger ME, Rosebrock L, Cacioppo J (2014) Frontal alpha EEG asymmetry before and after behavioral activation treat.ment for depression. Biol Psychol 99:198–208
Gratacos M, Gonzalez JR, Mercader JM, de Cid R, Urretavizcaya M, Estivill X (2007) Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. Biol Psychiatry 61:911–922
Haggard P (2008) Human volition: towards a neuroscience of will. Nat Rev Neurosci 9:934–946
Halari R, Simic M, Pariante CM, Papadopoulos A, Cleare A, Brammer M, Fombonne E, Rubia K (2009) Reduced activation in lateral prefrontal cortex and anterior cingulate during attention and cognitive control functions in medication-naive adolescents with depression compared to controls. J Child Psychol Psychiatry 50:307–316
Henter ID, de Sousa RT, Zarate CA Jr (2018) Glutamatergic modulators in depression. Harv Rev Psychiatry 26(6):307–319
Heresco-Levy U, Gelfin G, Bloch B, Levin R, Edelman S, Javitt DC, Kremer I (2013) A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 16:501–506
Hong Ng C, Norman TR, Naing KO, Schweitzer I, Kong Wai Ho B, Fan A, Klimidis S (2006) A comparative study of sertraline dosages, plasma concentrations, efficacy and adverse reactions in Chinese versus Caucasian patients. Int Clin Psychopharmacol 21:87–92
Howland RH (2008) Sequenced Treatment Alternatives to Relieve Depression (STAR∗D). Part 2: Study outcomes. J Psychosoc Nurs Ment Health Serv 46:21–24
Ide S, Ikeda K (2018) Mechanisms of the antidepressant effects of ketamine enantiomers and their metabolites. Biol Psychiatry 84:551–552
Iosifescu DV (2015) Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge. J Clin Psychiatry 76:738–740
Iosifescu DV et al (2009) Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol 19:772–777
Jesulola E, Sharpley CF, Bitsika V, Agnew LL, Wilson P (2015) Frontal alpha asymmetry as a pathway to behavioural withdrawal in depression: research findings and issues. Behav Brain Res 292:56–67
Khodayari-Rostamabad A, Reilly JP, Hasey GM et al (2013) A machine learning approach using EEG data to predict response to SSRI treatment for major depressive disorder. Clin Neurophysiol 124:1975–1985
Lally N, Nugent AC, Luckenbaugh DA, Niciu MJ, Roiser JP, Zarate CA Jr (2015) Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol 29:596–607
Leisman G, Moustafa AA, Shafir T (2016) Thinking, walking, talking: integratory motor and cognitive brain function. Front Public Health 4:94
Li CT, Su TP, Wang SJ, Tu PC, Hsieh JC (2015) Prefrontal glucose metabolism in medication-resistant major depression. Br J Psychiatry 206:316–323
Li CT, Chen MH, Lin WC, Hong CJ, Yang BH, Liu RS, Tu PC, Su TP (2016) The effects of low-dose ketamine on the prefrontal cortex and amygdala in treatment-resistant depression: a randomized controlled study. Hum Brain Mapp 37:1080–1090
Lin KM, Shen WW (1991) Pharmacotherapy for southeast Asian psychiatric patients. J Nerv Ment Dis 179:346–350
Lin CT et al (2008) Noninvasive neural prostheses using mobile and wireless EEG. Proc IEEE 96:1167–1183
Melo A, Leite-Almeida H, Ferreira C, Sousa N, Pego JM (2016) Exposure to ketamine anesthesia affects rat impulsive behavior. Front Behav Neurosci 10:226
Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, Iqbal S, Pillemer S, Foulkes A, Shah A, Charney DS, Mathew SJ (2013) Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 170:1134–1142
Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM, Lener M, Kautz M, Kim J, Stern JB, Price RB, Perez AM, Brallier JW, Rodriguez GJ, Goodman WK, Iosifescu DV, Charney DS (2015) Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 45:3571–3580
Nachev P, Kennard C, Husain M (2008) Functional role of the supplementary and pre-supplementary motor areas. Nat Rev Neurosci 9:856–869
Petryshen TL, Sabeti PC, Aldinger KA, Fry B, Fan JB, Schaffner SF, Waggoner SG, Tahl AR, Sklar P (2010) Population genetic study of the brain-derived neurotrophic factor (BDNF) gene. Mol Psychiatry 15:810–815
Phillips ML, Chase HW, Sheline YI, Etkin A, Almeida JR, Deckersbach T, Trivedi MH (2015) Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 172:124–138
Ressler KJ, Mayberg HS (2007) Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 10:1116–1124
Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L (2016) A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173:816–826
Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH (2017a) Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacology 42:2482–2492
Su TP, Chen MH, Chang WH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, Cheng CM (2017b) Dose-related effects of ketamine infusion on suicidal ideation in patients with treatment-resistant depression: a randomized double-blind controlled study in Taiwan, 5th AsCNP biennial meeting, Bali, Indonesia
Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, Foulkes A, Mathew SJ, Charney DS, Murrough JW (2015) Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 76:247–252
Wang J, Zhou M, Wang X, Yang X, Wang M, Zhang C, Zhou S, Tang N (2014) Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats. PLoS One 9:e99855
Wang LJ, Chen CK, Lin SK, Chen YC, Xu K, Huang MC (2018) Cognitive profile of ketamine-dependent patients compared with methamphetamine-dependent patients and healthy controls. Psychopharmacology (Berl) 235:2113–2121
WHO (2008) Projections of mortality and burden of disease, 2004–2030
Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, Sos P, Wang G, Zarate CA Jr, Sanacora G (2018) The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry 175:150–158
Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23:801–811
Zarate CA Jr, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, Moaddel R, Wainer IW (2012) Relationship of ketamine’s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry 72:331–338
Acknowledgements
We express our gratitude to all patients who kindly participated in this study. We thank all research assistants, physicians, pharmacists, and nursing staffs at D020 Unit of Taipei Veterans General Hospital for their assistance during the study process, without whom this work could not have been possible. We thank Mr. I-Fan Hu for his support and friendship. The participation of Dr. Krystal was supported by the US Department of Veterans Affairs via its support for the VA National Center for PTSD, the US National Institute on Alcohol Abuse and Alcoholism (P50AA12870, M01RR00125), and the US National Center for Advancing Translational Science (UL1 RR024139). None of the aforementioned funding organizations had any role in the study design, data collection, analysis, interpretation of result, writing of the report, and the ultimate decision to submit the paper for publication.
Funding and disclosures: The study was sponsored by grants from Ministry of Science and Technology, Taiwan (101-2314-B-010-060, 102-2314-B-010-060, 107-2314-B-075-063-MY3 and 108-2314-B-075-037), Taipei Veterans General Hospital (V106B-020, V107B-010, and V107C-181), and the Kun-Po Soo Medical Foundation in Taiwan.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Chen, MH., Su, TP. (2020). Effects of Adjunctive Ketamine Intravenous Infusion in Taiwanese Patients with Treatment-Resistant Depression: Antidepression, Antisuicidality, BDNF Val66Met, and Brain Imaging. In: Hashimoto, K., Ide, S., Ikeda, K. (eds) Ketamine. Springer, Singapore. https://doi.org/10.1007/978-981-15-2902-3_11
Download citation
DOI: https://doi.org/10.1007/978-981-15-2902-3_11
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-2901-6
Online ISBN: 978-981-15-2902-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)